Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Catalyst raises $40 million for Alterase therapies

This article was originally published in Scrip

Executive Summary

Catalyst Biosciences has raised $40.4 million to fund its Alterase engineered protease therapeutics, including its lead candidate, CB 813, for acute bleeding in haemophiliacs. The US company said that the series C round would fund its operations for several years and advance CB 813 through Phase I/II proof-of-concept studies. CB 813 is an improved factor VIIa that the firm believes will require less dosing to control acute bleeding episodes than other formulations. Catalyst expects to file an IND for clinical testing in early 2009. The investment was led by Essex Woodlands Health Venture, which will appoint Jeff Himawan as its representative on Catalyst's board of directors. Burrill & Company, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures and Sofinnova Ventures also participated in the round.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts